Otros idiomas Ono Pharmaceutical Co., Ltd.

Acciones

4528

JP3197600004

Mercado cerrado - Japan Exchange Otros sitios de cotización 08:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
2.300 ^JPY	+1,34 %		+2,77 %	-8,59 %

21/03	ONO Pharmaceuticals, Co., Ltd. anuncia que se ha completado la inscripción en el primer brazo del estudio PROSPECT de tirabrutinib en pacientes estadounidenses con LPSNC recidivante o refractario	CI
14/03	Sibylla Biotech inicia una colaboración estratégica para el descubrimiento de fármacos con Ono Pharmaceutical Co., Ltd. en trastornos del sistema nervioso central	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono	26/04
Ono Pharmaceutical : Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area	25/04
Ono Pharmaceutical : Announcement on Changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers	05/04
Ono Pharmaceutical : Announces Completion of Cancellation of Treasury Stock	29/03
Ono Announces General Sponsorship for the 'Theme Weeks' as Bronze Partner, at the Expo 2025 Osaka, Kansai, Japan	28/03
Ono Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford	25/03
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference	25/03
Ono Pharmaceutical : Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford	22/03
ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL	21/03
Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders	15/03
Ono Pharmaceutical : Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders	14/03
Sibylla Biotech Enters Strategic Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. in Central Nervous System Disorders	14/03
Ono Pharmaceutical : U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	12/03
Ono Pharmaceutical Co., Ltd. Enters into A University-Wide, Research Alliance Agreement with Harvard University	11/03
Ono Pharmaceutical : Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101	06/03
Ono Pharmaceutical Announces Status of Acquisition of Own Shares	04/03
Ono Pharmaceutical : Announces Status and Completion of Acquisition of Own Shares	04/03
Tranche Update on Ono Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 25, 2023.	04/03
Ono Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 25, 2023, has closed with 18,732,400 shares, representing 3.88% for ¥49,999.75 million.	01/03
Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets	20/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Ono Pharmaceutical Co., Ltd.

Acciones

4528

JP3197600004

Otros idiomas

Filtros